Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to four new employees to purchase an aggregate of 205,000 shares, effective March 2, 2026.
The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $24.02, equal to the last reported Nasdaq sale price on March 2, 2026.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
On the day this news was published, OLMA gained 3.88%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OLMA was down 0.74% ahead of this news, while close biotech peers were mixed (e.g., ARVN +2.93%, SAGE -0.69%, ORKA +1.05%), pointing to stock-specific trading rather than a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 19 | Conference presentation | Neutral | +1.1% | Announcement of CEO presentation at TD Cowen health care conference. |
| Feb 04 | Investor conferences | Neutral | -5.0% | Planned participation in multiple February 2026 investor conferences. |
| Feb 03 | Inducement grants | Neutral | +0.8% | Inducement stock options for two new employees under 2022 Inducement Plan. |
| Jan 30 | Executive departure | Neutral | -0.3% | Departure of Chief Operating and Financial Officer and interim finance transition. |
| Jan 05 | Inducement grants | Neutral | -0.2% | Inducement options for new employees with four-year vesting and 10-year term. |
Routine items like conferences and inducement grants have historically led to modest, mixed price reactions, suggesting limited standalone impact from similar disclosures.
Over the last few months, Olema has mainly reported corporate and governance updates. Multiple inducement grant announcements in January–February 2026 featured similar four-year vesting and 10-year terms with exercise prices set at the prior Nasdaq close, each followed by small price moves within about ±5%. Management changes and conference participations also produced modest reactions. Today’s inducement grant fits this pattern of routine equity-compensation and investor-relations news rather than a new clinical or financial catalyst.
Market Pulse Summary
This announcement details routine equity compensation: inducement stock options for four new employees covering 205,000 shares, vesting over four years with a 10-year term and a $24.02 exercise price. Similar grants in early 2026 also followed Nasdaq Listing Rule 5635(c)(4). In context with recent insider filings and board-approved plans, investors may focus on how cumulative option awards, vesting structures, and insider ownership trends evolve alongside future clinical, operational, or financing updates.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
exercise price financial
vesting financial
AI-generated analysis. Not financial advice.
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
